rs6511720 — LDLR Intron 1

The LDL Receptor's Regulatory Dial — A Variant That Tunes Cholesterol Clearance

The low-density lipoprotein receptor (LDLR) is the primary gateway through which your liver removes cholesterol from the bloodstream. Mutations in this gene cause the majority of familial hypercholesterolemia cases¹¹ Mutations in this gene cause the majority of familial hypercholesterolemia cases
LDLR mutations account for 80-85% of FH, a condition causing severely elevated LDL from birth, leading to premature cardiovascular disease. While pathogenic LDLR mutations are rare, the common variant rs6511720 in intron 1 represents a subtler regulatory change that affects how efficiently the gene is expressed. This variant was identified in genome-wide association studies as a significant modulator of LDL cholesterol levels²² identified in genome-wide association studies as a significant modulator of LDL cholesterol levels
Beta = -0.22 for LDL-C, p = 3.85 × 10⁻²⁶² in the Global Lipids Genetics Consortium meta-analysis of 170,607 individuals and coronary heart disease risk.

The T allele at rs6511720 is present in approximately 11% of people of European descent, 13% of those of African descent, but only 1% of East Asians³³ 11% of people of European descent, 13% of those of African descent, but only 1% of East Asians
Population frequency data from dbSNP and gnomAD, making this a moderately common protective variant with substantial ethnic variation. Each copy of the T allele is associated with lower LDL cholesterol levels and reduced risk of coronary heart disease.

The Mechanism

The rs6511720 variant sits within intron 1 of the LDLR gene, 2,015 bases downstream of exon 1⁴⁴ intron 1 of the LDLR gene, 2,015 bases downstream of exon 1
HGVS nomenclature: c.67+2015G>T, in a region that functions as a regulatory enhancer. The T allele creates a binding site for serum response element (SRE) transcription factors⁵⁵ binding site for serum response element (SRE) transcription factors
Luciferase reporter assays in Huh7 hepatocellular carcinoma cells demonstrated allele-specific enhancer activity, which are proteins that amplify gene transcription in response to growth signals and sterol levels. When functional studies tested the two alleles in liver cells, the rare T allele increased LDLR promoter activity by approximately 29% compared to the common G allele.

This enhanced expression translates directly to more LDL receptor proteins on the surface of liver cells. With more receptors available, hepatocytes can capture and internalize more LDL particles from the bloodstream⁶⁶ capture and internalize more LDL particles from the bloodstream
The LDLR binds apolipoprotein B-100 on LDL particles, triggering receptor-mediated endocytosis, lowering circulating cholesterol levels. The effect is subtle but meaningful: each T allele reduces LDL cholesterol by roughly 4-5 mg/dL on average.

The variant is in complete linkage disequilibrium with three other intron-1 SNPs⁷⁷ complete linkage disequilibrium with three other intron-1 SNPs
Including rs57217136, rs141787760, and rs60173709, which together form a haplotype, meaning these variants are inherited as a unit. The haplotype's combined effect on LDLR expression is approximately 29%, with each variant contributing through distinct transcription factor binding sites.

The Evidence

The association between rs6511720 and LDL cholesterol has been replicated across multiple large genetic consortia⁸⁸ replicated across multiple large genetic consortia
Including the Global Lipids Genetics Consortium (N=170,607) and validated in multiethnic cohorts, establishing this as one of the well-characterized lipid-associated variants. The T allele is associated with lower LDL-C levels (beta = -0.22 standard deviations) and correspondingly lower risk of coronary heart disease (odds ratio approximately 0.89, representing about 12% reduced risk per T allele).

Beyond baseline cholesterol levels, rs6511720 also affects response to statin therapy⁹⁹ response to statin therapy
In the JUPITER trial of rosuvastatin, rs6511720 was associated with 2.6% greater LDL-C reduction per T allele (p=0.005). This makes pharmacogenomic sense: statins work by inhibiting cholesterol synthesis in the liver, which triggers compensatory upregulation of LDLR expression. Individuals who start with genetically higher LDLR expression (T carriers) may achieve greater absolute reductions when statins further amplify receptor levels.

The functional mechanism was confirmed through luciferase reporter assays demonstrating the T allele's 29% increase in LDLR transcription¹⁰¹⁰ luciferase reporter assays demonstrating the T allele's 29% increase in LDLR transcription
Huh7 cells transfected with T allele constructs showed significantly higher promoter activity, and electrophoretic mobility shift assays proved that the T allele specifically binds serum response element (SRE) transcription factors. These experiments bridge the gap between genetic association and biological mechanism.

Interestingly, another common LDLR variant, rs688 in exon 12, interacts with rs5925 to regulate LDLR splicing efficiency¹¹¹¹ rs688 in exon 12, interacts with rs5925 to regulate LDLR splicing efficiency
The four possible haplotypes show splicing efficiencies ranging from 68.5% to 79.6%, affecting the proportion of functional LDLR transcripts. While rs6511720 modulates transcription, rs688 affects post-transcriptional processing, illustrating how multiple regulatory layers fine-tune LDLR expression.

Practical Implications

For individuals with the common GG genotype, standard cardiovascular prevention guidelines apply. Current recommendations emphasize LDL cholesterol targets based on cardiovascular risk¹²¹² Current recommendations emphasize LDL cholesterol targets based on cardiovascular risk
For general prevention, LDL <100 mg/dL; for high-risk patients with established disease, <70 mg/dL; for very high-risk patients, <55 mg/dL. Diet, exercise, and when indicated, statin therapy, remain the cornerstones of cholesterol management.

Those carrying one or two T alleles have a genetic advantage in cholesterol clearance, but this doesn't negate the importance of healthy habits. Dietary interventions can powerfully modulate LDL levels regardless of genetics¹³¹³ Dietary interventions can powerfully modulate LDL levels regardless of genetics
Soluble fiber (5-10 g/day) reduces LDL by 5-10%, plant sterols (2 g/day) by 5-15%. The Mediterranean dietary pattern, rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil¹⁴¹⁴ Mediterranean dietary pattern, rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil
Multiple studies demonstrate LDL reductions of 8-15% with adherence to Mediterranean diet, has been consistently shown to reduce cardiovascular events independent of baseline cholesterol levels.

If statin therapy is prescribed, T allele carriers may achieve target cholesterol levels with lower doses or see greater absolute reductions at standard doses. However, dose adjustments should always be made based on measured lipid responses rather than genetic prediction alone. Guidelines recommend checking lipid panels 4-12 weeks after starting or adjusting statin therapy¹⁵¹⁵ Guidelines recommend checking lipid panels 4-12 weeks after starting or adjusting statin therapy
Repeated every 3-12 months to assess adherence and response, with dosing titrated to achieve individual risk-based targets.

Interactions

The rs6511720 variant is in complete linkage disequilibrium with rs57217136, rs141787760, and rs60173709¹⁶¹⁶ complete linkage disequilibrium with rs57217136, rs141787760, and rs60173709
These four intron-1 variants form a haplotype with combined effects on LDLR expression, meaning they are inherited together. The protective T allele at rs6511720 virtually always occurs with the minor alleles at these linked positions, and their combined regulatory effects produce the observed 29% increase in LDLR expression.

Beyond the LDLR locus, cholesterol metabolism involves a network of genes. PCSK9 (proprotein convertase subtilisin/kexin type 9) negatively regulates LDLR by promoting receptor degradation¹⁷¹⁷ PCSK9 (proprotein convertase subtilisin/kexin type 9) negatively regulates LDLR by promoting receptor degradation
Loss-of-function PCSK9 variants like rs11591147 increase LDL receptor levels and reduce cardiovascular risk. Conversely, gain-of-function PCSK9 variants like rs505151 accelerate LDLR degradation and raise cholesterol. Individuals carrying both protective LDLR variants (like rs6511720 T) and protective PCSK9 variants would experience compounded benefits, while those with risk alleles at both loci might face elevated cholesterol from dual mechanisms.

The rs688 variant in LDLR exon 12 affects splicing efficiency when paired with rs5925¹⁸¹⁸ rs688 variant in LDLR exon 12 affects splicing efficiency when paired with rs5925
The combined haplotype influences what proportion of LDLR transcripts are properly processed. Someone carrying the rs6511720 T allele (high transcription) but also the rs688 T allele (reduced splicing) might see attenuated benefits, as more transcripts are produced but fewer are successfully spliced into functional protein. Conversely, optimal LDLR function would result from combining high transcription (rs6511720 T) with efficient splicing (rs688 C, rs5925 C).

APOB variants affect the ligand that LDLR recognizes¹⁹¹⁹ APOB variants affect the ligand that LDLR recognizes
Rare pathogenic APOB mutations cause familial hypercholesterolemia through defective receptor binding, while common APOB polymorphisms modulate cholesterol levels through effects on LDL particle composition. The ultimate cholesterol outcome reflects the interplay between hepatic LDLR expression (affected by rs6511720), receptor degradation (PCSK9), and ligand quality (APOB).